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Abstract
Camptothecins (CPTs) are cytotoxic natural alkaloids that specifically target DNA topoisomerase 
I. Research on CPTs has undergone a significant evolution from the initial discovery of CPT in the 
late 1960s through the study of synthetic small molecule derivatives to investigation of 
macromolecular constructs and formulations. Over the past years, intensive medicinal chemistry 
efforts have generated numerous CPT derivatives. Three derivatives, topotecan, irinotecan, and 
belotecan, are currently prescribed as anticancer drugs, and several related compounds are now in 
clinical trials. Interest in other biological effects, besides anticancer activity, of CPTs is also 
growing exponentially, as indicated by the large number of publications on the subject during the 
last decades. Therefore, the main focus of the present review is to provide an ample but condensed 
overview on various biological activities of CPT derivatives, in addition to continued up-to-date 
coverage of anticancer effects.
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INTRODUCTION
Camptothecin (CPT, 1, Fig. 1) is a pentacyclic alkaloid isolated by Wall et al.1 in the early 
1960s from the Chinese tree Camptotheca acuminata. This compound attracted immediate 
interest as a potential cancer chemotherapeutic agent due to its impressive activity against 
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leukemias and various solid tumors in experimental systems. Due to CPT's negligible water 
solubility, clinical trials were initiated using the water-soluble sodium salt (2) of CPT in the 
early 1970s. 2 The trials were suspended in the 1970s due to lower efficacy of 2, 
accompanied by unpredictable and severe levels of toxicity, including hemorrhagic cystitis 
and myelotoxicity. Interest in CPT then subsided for over a decade.3,4 Revived attention 
resulted from the breakthrough discovery of DNA topoisomerase I (Topo I) as a therapeutic 
target for CPT. This discovery put CPT back on the frontlines of anticancer drug 
development in the late 1980s.5-7 Accordingly, CPT's total synthesis, mechanism of action, 
structure–activity relationship (SAR), analog synthesis as well as pharmacology, 
formulation, drug delivery, preclinical studies and clinical trials have been studied 
extensively. Recent interesting research approaches include using prodrug concepts and drug 
delivery systems for CPT.8
As the result of these renewed research efforts, three CPT analogues, topotecan (TPT, 3),9 
irinotecan (CPT-11, 4),10 and belotecan (CKD-602, 5),11 received governmental approval 
for the clinical treatment of ovarian, small-cell lung, and refractory colorectal cancers. Three 
additional water-soluble analogues, exatecan (DX-8951f, 6)12-14 lurtotecan (GG-211, 
7),15,16 and sinotecan (8),17,18 are currently under clinical evaluation. Moreover, preclinical 
and clinical studies of non-water soluble CPT analogues, rubitecan (9-nitrocamptothecin, 
9),19,20 9-aminocamptothecin (9-AC, 10),21 gimatecan (11),22 karenitecin (BNP-1350, 
12),23 and DB-67 (13),24 are also ongoing. Interestingly, newly emerging 
homocamptothecin (hCPT) derivatives, BN-80915 (14, diflomotecan) and BN-80927 
(15),25,26 with a stabilized 7-membered hydroxylactone ring are currently undergoing 
clinical trials (Fig. 2). More recently, a CPT prodrug (16) and delivery systems (17-19) are 
also currently in clinical trials (Fig. 3.).8,27-29 Today, with three successful compounds in 
clinical practice (3–5) and 14 compounds in clinical development, CPT analogues have 
become highly relevant clinical anticancer compounds.
Between 1966 and 2012, over 5,000 publications (journal articles and patents) on CPT were 
recorded. This dramatic number of publications reflects the research intensity in this field, as 
well as the interplay of enthusiasm and setbacks encountered during almost 50 years. Some 
excellent reviews on CPT derivatives from a historical point of view are available.30-35 
Recently, several reviews on the distribution, sources, applications, total synthesis, and SAR 
correlations of CPT have been published,36-41 which cover the literature up to early 2005. 
However, since then, significant studies on new CPT derivatives have been carried out and 
published. A more comprehensive and up-to-date review is needed to describe such 
continued studies on anticancer and other biological activities, as well as rapid developments 
in the CPT field. This review presents more coverage not only in regard to structures and 
anticancer activities, but also other biological (antiviral, pesticidal, antiparasitic, 
antipsoriatic) effects of CPT-related derivatives.
2. Biological activity of CPT and related derivatives
2.1 Antitumor Activity
Following its isolation and structural elucidation in 1966, the naturally occurring CPT 
attracted considerable attention in the clinical community on the basis of its promising 
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antitumor activity in many in vitro and in vivo studies. In 1985, it was discovered that CPT 
inhibited the nuclear protein Topo I by a unique mechanism,42 which stimulated revived 
interest in CPT as an important lead compound and led to active and clinically useful 
anticancer drugs, such as the approved TPT (3) and CPT-11 (4). Their clinical success and 
intriguing mechanism of action stimulated great interest in further exploration of CPT 
derivatives with better antitumor activity; among them, several derivatives are now 
undergoing preclinical evaluation. Published reviews have covered the literature concerning 
CPT until the early part of 2003. Here, we present continued up-to-date coverage of CPT in 
regard to structure and anticancer activity from 2004 to 2012.
2.1.1 A and B ring modified CPT derivatives—Numerous SAR studies have shown 
that substitutions in positions 7, 9, 10 are tolerated or can substantially increase anticancer 
activity. In particular, both TPT (3) and SN-38 (7-ethyl-10-hydroxy-camptothecin), the 
hydrolysis product and active metabolite of irinotecin (4) in which the carbamate group has 
been removed, have an OH substituent at position 10, which seems to be important either to 
increase water solubility or decrease unwanted stabilization of the open hydroxyacid form 
by human albumin. A recent X-ray crystallographic analysis of a ternary complex between a 
topo I construct, a DNA oligonucleotide and 3 indicated that modifications at the 7- and 9-
positions of CPT would not interfere with drug–protein interactions. Furthermore, 
substitution at positions 7–10 and fusion of an additional ring on the A/B ring have led to 
potent compounds now in clinical studies, such as gimatecan, silatecan, lurtotecan, and 
exatecan. These successful examples imply that these positions can tolerate a large group 
and a wide possibility for structural modification. Accordingly, CPTs with lipophilic 
moieties at position 7 have been synthesized, including compounds with variously 
substituted C=N groups linked to the CPT scaffold via iminomethyl or oxyiminomethyl 
moieties. With one exception (20), several oxyiminomethyl substituted compounds (21-23) 
exhibited potent cytotoxic activity in vitro and in vivo comparable or superior to TPT (3).43
In a further study, Dallavalle et al.44 synthesized a series of imines (24-40) derived from 
camptothecin-7-aldehyde and variously substituted aromatic amines and evaluated their 
cytotoxicity against tumor cell line H460. All of the prepared 7-aryliminomethyl CPT 
imines exhibited potent cytotoxic activity superior to that of 3 under the same conditions 
(Table 1).
Subsequently, a series of 9-substituted CPTs (41-52) derived from 9-formylcamptothecin 
were synthesized by the same group;45 most of the new compounds showed higher cytotoxic 
activity than 3 (Table 2). Moreover, these compounds induced comparable DNA damage 
comparable to that of the reference compound SN-38. A molecular docking study suggested 
that the small polar 9-substituents interacted favorably with the topo I–DNA complex, which 
is consistent with their higher activity relative to corresponding 7-substituted CPTs.
You et al.46 reported a series of 7-cycloalkylcamptothecin derivatives (53-66). As shown in 
Table 3, many of the compounds exhibited IC50 values in the low μM to nM level and were 
up to 40-fold more potent than 3, the reference compound.
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The authors’ laboratories also designed and synthesized a series of 7-acyl CPT derivatives.47 
All of the new compounds showed significant inhibition of human tumor cell (A-549, 
DU-145, KB, and KBvin) growth, with IC50 values ranging from 0.0154 to 13.3 μM. 
Interestingly, while compound 67 showed a five-fold decrease in potency against KB-vin 
(IC50 = 0.13 μmol/L) compared with the KB cell line (IC50 = 0.023 μmol/L), compound 68 
showed a two-fold increase in potency against the former cell line.47
Several 7-alkynyl CPT derivatives (69–74) were recently prepared via copper-free 
Sonogashira coupling by Xiao et al.48 As shown in Table 4, most of the compounds were 
less cytotoxic than SN-38, but were generally more potent than 3. Some of the new 
compounds showed almost equal cytotoxicity to SN-38 against Eca-109 and SGC7901 
cells.48
Eighteen novel water soluble derivatives were designed based on the structures of 4 SN-38. 
Most of the new compounds possessed lower cytotoxicity compared with CPT. However, 
compound 75 exhibited potent cytotoxicity similar to CPT with IC50 less than 0.01 nM 
against KB and HCT-8 cancer cell lines, and compounds 76-78 showed similar or superior 
cytotoxic activity to 3.49
Seventeen 10-arylcamptothecins were synthesized by Suzuki cross-coupling chemistry.50 
Some of the derivatives showed very potent cytotoxicity in preliminary in vitro cytotoxicity 
testing with IC50 values on the order of 9 nM. 10-(4-Pyridyl)camptothecin (79) and its water 
soluble hydrochloride 80 displayed comparable potency to 3 in various assays. Mechanistic 
studies indicated that 79 and typical CPT derivatives had similar pharmacological profiles in 
topo I inhibitory and cell cycle arrest assays.
Gao et al.51 reported a new synthetic strategy using a Claisen rearrangement reaction to 
modify 10-allyloxy-7-ethylcamptothecin and generatc a series of 7-ethyl-9-alkyl derivatives 
(81-86) of CPT. As shown in Table 5, all of the new compounds exhibited significant in 
vitro cytotoxic activity against four tested tumor cell lines with IC50 values ranging from 
0.012 to 3.84 μM, and were as or more potent than 3. The biological results suggested that 
the small alkyl groups at the both 7- and 9-positions of CPT could promote liposolubility, as 
well as antitumor activity in vitro and in vivo, but did not increase stability of the lactone.51
Recently, a novel series of A-ring modified hexacyclic CPT derivatives containing a 1,3-
oxazine ring were first designed and synthesized by Wang and coworkers.52 All of the new 
compounds were assayed for in vitro cytotoxicity against nine human cancer cell lines and 
most of them showed impressive cytotoxicity. Compounds 87 and 88 showed the highest 
potency against several cell lines. Moreover, compound 88 (IC50 = 0.01 μM) was about 13-
fold more potent than CPT (IC50 = 0.13 μM) and about 6-fold more potent than 3 (IC50 = 
0.06 μM) against HEPG-2.52
Subsequently, several hexacyclic CPT analogs were designed by Niizuma et al.53 based on 
the proposed structure of the topo I/DNA/CPT ternary complex. Remarkably, compound 89 
exhibited in vivo antitumor activities superior to 4 in human cancer xenograft models in 
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mice at maximum tolerated doses, although its in vitro antiproliferative activity was 
comparable to SN-38 against corresponding cell lines.53
Glucuronide prodrugs are useful in antibody-directed enzyme prodrug therapy (ADEPT), 
because extracellular β-glucuronidase in tumor cells can be targeted by administration of 
antibody–β-glucuronide conjugates. Recently, a β-glucuronidase activated prodrug approach 
was applied to 9-aminocamptothecin and 10-hydroxycamptothecin. Compound 90, a 
glucuronide derivative of 9-aminocamptothecin (9). is a promising β-glucuronidase-
cleavable prodrug. It was less toxic than 9 against human tumor cell lines, but upon enzyme 
activation, displayed similar cytotoxicity to that of the parent drug. Furthermore, compound 
90 showed promising in vivo prodrug properties and activity. Therefore, the same approach 
was applied to 10-hydroxycamptothecin, and the resulting compound (91) was 80 times 
more soluble than 10-hydroxycamptothecin in aqueous solution at pH 4.0 and stable in 
human plasma. Prodrug 91 was 10- to 15-fold less toxic than the parent drug against HepG2, 
Colo205, HT29, and H928 cell lines with IC50 values 56.5, 94.2, 97.8, 91.1 nM, 
respectively. Molecular modeling studies predicted that compound 91 would have a higher 
binding affinity to human β-glucuronidase than compound 90. 54
2.1.2 C and D ring modified CPT analogues—Historically, SAR efforts have largely 
focused on the A, B, and E rings of CPT. Relatively few D ring analogues have been 
investigated. Two early examples, 14-chloro and 14-nitro derivatives, were much less 
cytotoxic than the parent CPT, suggesting a lack of tolerance for substitution at that 
position.55-57 Recently, Hecht and coworkers58 synthesized a water-soluble 14-aza CPT 
(92), which is a hybrid between luotonin A and CPT. Compound 92 stabilized the topo I-
DNA complex at the same sites as CPT and was cytotoxic with a similar but somewhat 
higher IC50 value then CPT. Further, the new compound mediated inhibition of DNA 
relaxation more effectively than CPT and possessed a faster off-rate from the ternary 
complex than CPT. It appeared that replacing the C14-H group with N augments the ability 
to form the ternary complex while concomitantly reducing the lifetime of the formed 
complex, thus reducing the cytotoxic effects of the resulting analogue.58 Therefore, water-
soluble 14-aza CPT represents an attractive core structure toward the development of a CPT 
analogue with useful therapeutic properties.
The synthesis and biological evaluation of the CPT thiopyridone isostere, thiocamptothecin 
(TCPT, 93) were accomplished by using Lawesson's reagent. Significantly, TCPT was more 
potent than the parent compound against H460, HT29, and IGROV-1 cell lines. The 
increased cytotoxic potency of 93 versus CPT was even more evident against HT29 colon 
carcinoma cells and the subline HT29/mit. Also, compound 93 caused slightly more DNA 
damage to that observed for CPT, but an identical DNA cleavage pattern.59
More recently, Duan et al.60 synthesized 14-aminocamptothecins 94 and 95. These two 
compounds exhibited excellent cytotoxic potency against human tumor cell lines in vitro, 
and were not substrates for any of the major clinically relevant efflux pumps (MDR1, 
MRP1, and BCRP). Compounds 94 and 95 showed similar cytotoxicity against human and 
mouse bone marrow progenitor cells. In contrast, many CPT analogues are substrates for 
efflux pumps and are dramatically more toxic to human relative to murine marrow cells. 
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Compounds 94 and 95 demonstrated significant brain penetration when dosed orally in 
mice. Compound 94 showed significantly better efficacy relative to 3 when dosed orally in 
three ectopic xenograft models, H460, HT29, and PC-3.60
So far, few studies have featured C-ring synthetic modifications, probably because of the 
low anticancer activity observed with certain reported analogues, including 5-hydroxy, -
alkoxy, -acyloxy, -hydroxymethyl, and -amino substituted derivatives,61-63 as well as 
contradictory studies on 5-substituted CPT derivatives. For example, 5-propionyl and 5-
ethoxy derivatives bearing a hydroxy, methoxy, or fluoro group at the β-position showed 
good antitumor activity. One of these analogues, DRF-1042, is currently in phase II clinical 
trials.64 These findings prompted other studies to investigate the role of modification at the 
C-5 position. In 2009, using an enolate chemical protocol, in addition to C5-alkylated 
derivatives, new C5-fluorinated (96) and -aminated analogues (97), along with the first six-
membered ring CPT derivative (98) were synthesized and tested for antiproliferative activity 
against human non-small-cell lung cancer carcinoma NCI-H460. The new compound was 
less active than 3 and SN-38, but caused similar DNA patterns to that of SN-38.65
2.1.3 E ring modified CPT analogues—Recent work on CPT has focused on 
construction of ester prodrugs at the C-20 position particularly aimed at new forms of 
administration (especially on a nanoscale) to optimize drug delivery. For example, 
Deshmukh et al.66 recently synthesized a series of α-amino acid ester prodrugs of CPT. A 
successful example from this work is afeletecan (CPT glycoconjugate, 99), a C-20 
glycoconjugated, clinical prodrug. Compound 99 was the best candidate for a passively 
targeted sustained release lung delivery system.
In addition, a series of nitrogen-based 20(S)-hydroxyl CPT ester derivatives were prepared 
by Wang et al.67 These ester compounds showed comparable or superior cytotoxic activity 
to 3, but most of them were less cytotoxic compared with CPT. As shown in Table 6, 3-
aminopropionates (100–110) were more cytotoxic in vitro against several human tumor cell 
lines than 3-amidopropionates (111, 112). The 3-(6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinin-2-yl)propionate ester 110 showed the best antitumor activity in vivo and 
in vitro among all compounds prepared.
Other nitrogenous heterocyclic groups have been introduced at CPT's 20-position to increase 
water solubility and improve activity. For example, compounds 113 and 114 modified with 
pyrazole acetates showed notable antitumor activity and lactone stability. Compound 114 
achieved a tumor inhibitory rate (TIR) of 92.9% at a dose of 20 mg/kg (similar to the TIR of 
CPT at a dose of 10 mg/kg) and showed a better dose-efficacy relationship. Compound 113 
achieved a TIR of 75.6% at a dose of 20 mg/kg. Compounds 113 and 114 were less toxic in 
mice than CPT based on change of body weight before and after administration.68
Based on previous work on nitroxyl free radicals as well as the fact that L-amino acids are 
actively transplanted into mammalian tissue, have good water solubility, and are often used 
as carrier vehicles for some drugs, the authors linked a nitroxyl radical moiety (1-
oxyl-2,2,5,5-tetramethylpyrroline-3-carboxylic acid) at the 20-hydroxyl of CPT via different 
hydrophilic amino acid spacers to synthesize a series of novel spin-labeled CPT derivatives 
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(115-119). Compounds 115-119 showed similar or better in vitro cytotoxicity than the 
parent drug CPT and the clinically available drug 4 against human bladder cancer T-24.69
Recently, Hecht et al.70 reported the effects of replacing the C-20 and C-21 O-atoms with S-
atoms (120, 121). 20-Mercapto CPT (120) stabilized the topo I-DNA covalent binary 
complex at the same site as CPT, but was less cytotoxic than CPT. The dimercapto CPT 
analog 121 had only a very slight effect on stabilization of the topo I-DNA complex and was 
not cytotoxic.
2.1.4 A, B, and E ring modified CPT analogues—The β-hydroxy-ε-lactone E-ring of 
hCPTs is generally more stable and hydrolyses less rapidly than the classical α-hydroxy-ö-
lactone of CPTs.71 In addition, the resulting ring-opened compound is an isolable product 
that does not spontaneously recyclize. Subsequent investigation of various A- or B-ring 
derivatives showed that some hCPTs are more potent topo I poisons than CPT and exhibit 
greater antiproliferative activity than CPT in both parental and CPT-resistant cell lines, 
particularly prostate cell lines. One highlight of these first structural studies was 
diflomotecan (14), a 10.11-difluoro-hCPT, which showed high in vitro cytotoxicity, 
promising in vivo efficacy, and was the first hCPT to enter clinical trials.72,73
As described previously, substituted C=N bonds increased antitumor activity in 
aryliminomethyl and oxyiminomethyl CPT analogues. Therefore, a series of novel 9-
benzylideneamino derivatives of hCPT were designed with various substituents, including -
Me, -NMe2, and -OMe, on the benzylidenamino residue. The resulting derivatives showed 
excellent cytotoxic and topo I inhibitory activities. Compared with 3, compounds 122–125 
showed greater growth inhibition (IC50 2.3–9.8 nM) against breast cancer cells.74
Subsequently, the same research group also published a bioisosteric series of compounds 
(126-141) bearing a C=C bond as a linker. From the results shown in Table 7, several hCPT 
compounds with an alkenyl or an (alkoxycarbonyl)ethenyl group exhibited good cytotoxic 
activity comparable or superior to 3 against A-549 cancer cells.75
The high cytotoxicity of hCPT derivatives prompted Zhang et al.76 to investigate a series of 
water-soluble 10-phosphate esters. Most of the resulting compounds displayed moderate 
cytotoxicity against three tested cell lines (142–149, Table 8). From a structure-activity 
relationship (SAR) viewpoint, the cytotoxicity of the phosphodiesters was lower than that of 
the phosphotriesters and the length of the phosphate alkyl chain affected the potency. 
Compound 146 with dibutyl phosphate group showed greater tumor inhibitory activity than 
4 in a A549 xenograft model, potent activity in a DNA cleavage assay at a concentration of 
100 μM, and good stability at both pH 7.4 and 3.0. 76
Seven new 7-trifluoromethylated hCPT derivatives were prepared by Zhu et al.77 Three 
derivatives (150-152) possessed higher in vitro antitumor activity than 3. Further in vitro 
and in vivo results provided convincing evidence that the 7-position of hCPT is a favorable 
site for introduction of a trifluoromethyl group.
To further promote lactone stability, Lu et al.78 recently synthesized a series of hCPTs 
bearing a hydroxy or acetoxy group at the α-position of the E-ring β-hydroxy-ε-lactone 
Liu et al. Page 7













(153-160). Compared with 10-hydroxycamptothecin (10-HCPT) and CPT, most of the new 
compounds exhibited similar or better cytotoxic activity against HCT116 and A549 cells. 
When assayed for topo I inhibition, some compounds displayed potent activity at 100 or 10 
μM, equal or superior to the activity of CPT (1), SN-38, and 10-HCPT. Moreover, 
compound 159 retained 90% and 60% of the lactone form after incubation at 37 °C for 8 h 
in phosphate buffered saline (PBS) at pH 7.4 and in PBS containing human serum albumin 
(HSA), respectively, while CPT retained only 30% and 18%, respectively. Therefore, the 
introduction of a second oxygenated substituent in the seven-membered E-ring is feasible 
and produces effective agents for the treatment of human cancer.78
Based on accumulated SAR studies and critical modeling clues, modifications at the 7-
position appear to be the most efficient approach to increase the antitumor potency of CPTs. 
Furthermore, the crystal structures of topo I-DNA in complex with CPT revealed that C-7 
substituents extended into the major groove of DNA, which could reinforce the stability of 
the inhibitor-topo I-DNA covalent complex. Recently Liu et al. presented a postulated 
binding mode of the hCPT compound class with the DNA-Topo I complex. In this model, 
they found a large space around the C-7 position of hCPT that allowed the introduction of 
substituted acyl groups with preservation of two key hydrogen bonds. Accordingly, they 
designed and synthesized a series of novel 7-acyl derivatives of hCPT. Compounds 161-163 
showed highly potent cancer cell growth inhibitory activity with the IC50 values in the range 
of 1 nM to 2.2 nM against A549, MDA-MB-435, and HCT116 tumor cell lines.79
Li et al recently synthesized a series of five-membered E-ring CPT derivatives. Consistent 
with previous observations that five-membered E-ring analogs were inactive with respect to 
Topo I inhibition, the new racemic analogs generally exhibited markedly reduced cytotoxic 
activity against tested tumor cell lines. With IC50 values of 1.28 and 2.03 μM against A549 
and HT-29 cancer cell lines, only compound 163 showed similar cytotoxic activity to 3.80
Recently, due to the important role of fluorine substitution in drug design, a series of (20S,
21S)-21-fluorocamptothecins were designed and synthesized. All of these analogues showed 
potent in vitro antitumor activities and were potent Topo I inhibitors with increased 
hydrolytic stability. Among them, 7-cyclohexyl-21-fluorocamptothecin (165) exhibited the 
best antiproliferative activity against all three tested cancer cell lines (IC50 range: 0.71−0.07 
μM), which was two-fold (A549) and six-fold (HCT116) more active than CPT. This 
compound represents a promising lead for further optimization.81
In continuing these efforts, our group recently reported that a series of 20-sulfonylamidine 
CPT derivatives displayed potent antitumor activity with significantly different drug-
resistance profiles from those of CPT. Among them, compound 166 was more active than 4 
against the growth of A549, DU-145, KB, and KBvin with IC50 values of 0.031, 0.050, 0.14, 
and 0.026 μM, respectively. Mechanistically, 166 induced significant DNA damage by 
selectively inhibiting Topo I and activating the ATM/Chk related DNA damage-response 
pathway. In mouse xenograft models, 166 demonstrated significant activity without overt 
adverse effects at 5 and 10 mg/kg, with two and three mice, respectively, among groups of 
eight undergoing complete regression. Notably, 166 at 300 mg/kg (i.p.) showed no overt 
acute toxicity in contrast to CPT (LD50 56.2 mg/kg, i.p.) and 4 (LD50 177.5 mg/33 kg, i.p.). 
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Thus, 166 is attractive as a potential candidate for anticancer chemotherapy and the 
modification with sulfonylamidine-substituted side chains may overcome some limitations 
of CPT.82
2.2 Antiviral activity
Besides anticancer activity, antiviral activity is another outstanding property of CPT and 
many of its derivatives. Topoisomerase I activity has been associated with various 
retroviruses including Rous sarcoma virus, 83,84 Molone murine leukemia virus,85 equine 
infectious anemia virus, and human immunodeficiency virus (HIV).86 Therefore, several 
studies have been conducted with CPT in order to elucidate the role of topo I in various 
retroviral functions.87 Horwitz et al.89 showed that CPT inhibited DNA and RNA synthesis 
in HeLa cells and induced DNA degradation, and then designed an experiment to determine 
whether it would inhibit growth of viruses that replicate in the cytoplasm of a host cell. 
Results indicated that CPT inhibited DNA synthesis in HeLa cells at a concentration of 10 
μM. Inhibition of viral DNA synthesis was observed when CPT was added at 1 or 2 hours 
after infection.89 Priel et al.90 reported that non-cytotoxic doses of CPT inhibited HIV 
replication in acute infection of H9 cells at a high efficacy (>90%). Moreover, CPT inhibited 
EIAV replication in chronically infected Cf2Th cells. Continuous exposure of these cells to 
CPT for 52 days revealed 85 to 92% inhibition of virus production. Cell viability and growth 
rate were not affected.91
CPT inhibited HIV-1 LTR activity and viral production in cultures of human cells 
expressing HIV-1 LTR activity and cells chronically infected with HIV-1, respectively.92 
The mechanism of HIV-1 infection and the progression of immunosuppression were 
associated with activation of latent virus, which in turn was regulated by the long terminal 
repeat (LTR) in viral (proviral) DNA.93 Based on these results, CPT may interact with a 
protein that either binds to the LTR or is involved in the posttranscriptional process.
Furthermore, some CPT analogues have been evaluated for antiviral activity. TPT (3) was 
efficient in treatment of AIDS-related progressive multifocal leukoencephalopathy.94 Sadaie 
et al.95 reported that 9-nitrocamptothecin (9) inhibited HIV-1 replication in freshly infected 
U937 monocytoid cells. Subsequently, the authors also investigated in vitro anti-HIV 
activities (including HIV-1 and HIV-2) of 10-hydroxy-CPT (167) and 7-hydroxymethyl-
CPT (168).96 The results demonstrated that 168 showed more potent anti-HIV activity than 
CPT, while 167 was less active. Taken together, the above studies indicate that CPT can 
serve as a valuable lead compound for developing a new anti-retroviral drug.
A few studies have demonstrated that CPT is a potent inhibitor of replication, transcription, 
and packaging of double-stranded DNA-containing adenoviruses, papovaviruses, and single 
stranded DNA-containing autonomous parvoviruses. These findings indicated that CPT 
analogues could be developed for use as potent drugs against DNA viruses. Some 
researchers have reviewed the literature focusing on antiviral potential.97,98
Yamada and coworkers99 showed that CPT is active against human HSV-2 due to drug 
inhibition of host cell Topo I, which was apparently involved in the process of transcription, 
but not in the elongation step of HSV-2 DNA synthesis. In addition, mappicine ketone 
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(MPK, 169), a decarboxylated E-ring CPT analogue, has recently been identified as an 
antiviral agent with selective activities against HSV-1, HSV-2, and human cytomagalovirus 
(HCMV) with PR50 values of 2.9, 0.5, and 13.2 μM, respectively. MPK appears to be 
herpesvirus-selective; it does not inhibit other DNA or RNA viruses. Although its 
mechanism of action has not been determined, MPK functions differently from acyclovir 
(ACV) as demonstrated by the observation that ACV-resistant HSV-1 and HSV-2 are 
inhibited by MPK and that MPK resistant mutants are sensitive to ACV at HSV-1 wild-type 
virus levels.100,101 More recently, the authors assessed the in vitro antiviral efficacies of 
CPT analogues against herpes simplex virus type 2 (HSV-2) in Vero cells.103 Several 
compounds exhibited similar or better antiviral activity than ACV against HSV-2 in vitro. 
Among them, compound 170 was the most potent with an IC50 value of 1.3 μg/mL and 
selectivity index (SI) of 27.04.
2.3 Pesticidal activity
In ancient China, the crude extract of C. acuminate containing CPT has been used 
traditionally to control insect pests for centuries, and it was reported to be a potent 
chemosterilant against the housefly and cabbage caterpillar.103,104 It also exhibited 
significant inhibitory activities against several agricultural pests like Empoasca vitis, 
Mythimna separate Walker, Brevicoryne brassicae, Nilaparvata lugens, and Chilo 
suppressalis, supporting its potential use as a field pesticide.105-108 Additionally, a recent 
study showed that CPT could cause visible changes in the midguts from the lepidopteran 
pests Trichoplusia ni and Spodoptera exigua, such as losing the single layer of epithelial 
cells and disrupting the peritrophicmembrane.109 Investigations by Zhong et al.110 also 
demonstrated that CPT-induced apoptosis in SL-1 cells and midgut cells of S. litura. 
Consistent with these results, Zhang et al.111 recently revealed that CPT caused Sf21 and 
IOZCAS-Spex-II cell apoptosis via a mitochondrial-dependent apoptosis signal transduction 
pathway, suggesting that its mode of action may be related to apoptosis. Moreover, 
pretreatment with CPT led to reduction in both the enzymatic activity and the steady 
accumulation of the Topo I protein in IOZCAS-Spex-II cells despite up-regulation of its 
mRNA expression in response to the treatment.112 In connection with these efforts, in order 
to find new CPT-derived insecticides with improved profiles and to clarify the structure–
activity relationships of campothecin analogues, a number of CPT derivatives modified in 
the different positions have been synthesized and evaluated their insecticidal activity against 
some important insect pests by our group;113-117 among which, some compounds exhibited 
insecticidal activity equal to or higher than that of CPT. For example, we synthesized a 
series of spin-labeled CPT derivatives by esterifying the 20-hydroxyl of CPT with L-amino 
acids containing a nitroxyl radical moiety and evaluated their antifeedant and insecticidal 
effects against third-instar larvae of Mythimna separate. In the antifeedant bioassays, the 
spin-labeled compounds were less potent than CPT.113 All of the derivatives showed 
delayed insecticidal activity, which was different from traditional neurotoxic insecticides. 
Furthermore, eight spin-labeled CPT analogues (172-179) were synthesized based on 5-(2’-
hydroxythoxy)-20(S)-camptothecin (171). When tested against fifth-instar larvae of 
Brontispa longissima, compounds 171 and 172 showed promising insecticidal activity with 
corrected mortality rates of 69.55% and 74.07%, respectively.115
Liu et al. Page 10













Recently, a series of CPT derivatives via alkylation, oxidation, and esterification at the 5-, 
7-, and 20-positions were synthesized. Among them, compounds 7-CH2OH-CPT, 7-COOH-
CPT, and 10-OCH3-CPT displayed higher antifeedant activity (>90%) than CPT against 
third-instar larvae of Spodoptera litura at 24 h and 48 h. In addition, several compounds, 
including 7-CH2C6H5-CPT, 7-CHO-CPT, 7-CH2OCOC6H5-CPT, 10-O-CH2OCOC6H5-
CPT, 20-CH2OCOC6H5-CPT, and 20-F-CPT exhibited more potent nematocidal activity 
(LC50 2.28, 2.21, 1.37, 1.68, 0.13, and 1.71 mg/L, respectively) against Bursaphelenchus 
xylophilus than CPT (LC50 12.18 mg/L) after 24 h.116,117
More recently, we also investigated a large variety of CPT analogues for antifeedant activity 
against Spodoptera litura. Several compounds, including 20-SH-CPT,21-N-amino-CPT 
lactam, and 7-acetyl-CPT, displayed more potent antifeedant activity than CPT (Table 
10).118
On the other hand, plant-derived CPTs can be used to deter and eliminate termites, 
particularly subterranean species. Pure or raw water-insoluble CPT and its analogs may be 
useful in termite control strategies as barriers at higher concentrations (>50 ppm) by 
preventing termites from colonizing or feeding on particular substrates and structures or as 
toxicants in termiticides and baits particularly at lower concentrations.119
2.4 Antiparasitic activity
African trypanosomes (Trypanosoma brucei species) are parasitic protozoa that cause lethal 
diseases in humans and cattle. Studies showed that CPT was cytotoxic to African 
trypanosomes and related pathogenic hemoflagellates.120 CPT generated covalent DNA–
topoisomerase complexes with both nuclear and kinetoplastic preparations of DNA from 
trypanosomes, leishmanias,121 and other protozoan parasites of medical importance. Bodley 
et al.122 showed that CPT inhibited the nuclear and mitochondrial topo I of T. brucei thus 
blocking DNA replication and inducing the death of bloodstream trypomastigotes (IC50 = 
1.6 μM). In SAR studies, Bodley et al.123 also tested a series of CPT analogues for their in 
vitro effectiveness against African trypanosomes and found that their cytotoxicity was 
closely correlated to the ability to promote the formation of covalent protein–DNA 
complexes. This finding indicated that the sole cellular target of these agents is the parasite's 
topo I. Significantly, antiparasitic activity was increased by addition of substituents to the 
parent ring system (e.g. 10.11-methylenedioxy or ethylenedioxy groups, 7-alkyl groups, or 
9-amino or 9-chloro substituents) (Table 11). Among them, 9-substituted-10,11-
methylenedioxy derivatives were significantly more active than CPT against T. brucei 
bloodstream trypomastigotes. For example, 9-chloro-10,11-methylenedioxy-CPT (IC50 
0.041 μM) was 40 times more potent than CPT (IC50 1.6 μM). Although these CPT 
derivatives were still more toxic against mammalian cells than trypanosomes, selective 
toxicity might be achievable using this lead compound as a starting point.
Recently, Werbovetz et al.124 further examined CPT and four 10,11-methylenedioxy 
analogues the against pathogenic protozoan Leishmania donovani in vitro. Compared with 
CPT, 10,11-methylenedioxy-CPT (180) exhibited 90-fold greater antileishmanial activity 
(EC50 0.064 mM). Introduction of difluoro substitution at the methylene position (181) 
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reduced the activity, while introduction of a chloro (182) or amino (183) group at position 9 
resulted in two-fold greater activity than 180.
Furthermore, Proulx et al.125 3xplored tested the efficacy of free and liposome-loaded CPT 
against leishmaniasis, the parasite burden was significantly reduced when infected mice 
were treated with 2.5 mg/kg body weight CPT via intraperitoneal injections of free and 
liposomal CPT. Its excellent index suggested that a liposomal delivery may be exploited as a 
potential strategy against visceral leishmaniasis.
2.5 Antipsoriasis activity
Psoriasis is a chronic inflammatory skin disease characterized by epidermal keratinocyte 
hyperproliferation, abnormal differentiation, and inflammatory infiltration. Since the early 
1970s, several reports of topical preparations of Camptotheca or CPT in treatment of 
psoriasis have been published.126-129 these early studies showed that, as a topoisomerase 
inhibitor, CPT is effective in psoriasis therapy. Recently Wang et al.130 also reported that 
10-hydroxy-CPT exhibited significant curative efficacy in treatment of psoriasis. 
Subsequently, Lin et al.131,132 revealed that CPT and iso-CPT inhibited the growth of 
cultured normal human adult keratinocytes in vitro by inducing apoptosis. Furthermore, 
study by Lin et al.133,134 demonstrated that the therapeutic mechanism of CPT in psoriasis 
may be associated with its antiproliferative activity and apoptosis of keratinocytes through 
down-regulation of telomerase activity.
2.6 Antifungal/ Antimicrobial activity
Del Poeta et al.135 evaluated antifungal activity of CPT and its analogues in vitro against an 
isogenic series of S. cerevisiae strains including wild-type, △erg6 permeable mutant, △erg6 
△top1 double mutant, and △erg6△top1 mutant strains expressing C. neoformans topo I. 
They found that some derivatives were extremely active antifungal agents with minimum 
inhibitory concentrations (MICs) of less than 0.09 μg/mL when the strain contained 
overexpressed cryptococcal topo I. Particularly, a 10,11-methylenedioxy system in ring A 
(184 and 185), increased interaction with the fungal topo I. These findings suggested that 
CPT and certain derivatives can efficiently target the C. neoformans topo I enzyme to 
produce antifungal activity. Considering CPT's potent antifungal activity, Li et al.136 
evaluated CPT against Alternaria alternata, Epicoccum nigrum, Pestalotia guepinii, 
Drechslera sp., and Fusarium avenaceum. CPT inhibited mycelial growth by approximately 
50% (EC50) at 10–30 μg/mL and fully inhibited growth at 75–125 μg/mL. Recently, Zhang 
et al.137 also reported that CPT was effective against Rhizoctonia solani, Sphaerotheca 
fuliginea, and Pseudoperonospora cubensis under greenhouse and field conditions. Under 
greenhouse conditions, the IC50 and IC90 values of CPT against the three plant pathogens 
were 41.96 mg/L, 40.49 mg/L, 27.48 mg/L, and 756.77 mg/L, 247.02 mg/L, 341.81 mg/L 
respectively. Under field conditions, CPT also showed high inhibitory effects against the P. 
cubensis pathogen; the IC50 and IC90 values were l1.22 mg/L and 69.12 mg/L, respectively.
More recently, Alaghaz et al.138 synthesized a series of 10-substituted CPT 
phosphorothioate analogues and evaluated their antifungal /antimicrobial activity against 
fungal strains Aspergillus niger, Aspergillus flavus (molds), S. cerevisiae, C. albicans, T. 
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longifucus, A. flavus, M. canis, F. solani, and C. glaberata (yeasts). However, none of the 
tested compounds affected fungal growth significantly.
2.7. HIF-1 inhibitory activity
Hypoxia hypoxia-inducible factor 1(HIF-1) has attracted considerable attention as a 
molecular target for new antitumor agents because of its involvement in various aspects of 
cancer cell biology. In 2002, researchers at the National Cancer Institute screened 2000 
diverse compounds for functional inhibition of hypoxia-inducible factor 1 (HIF-1), a master 
regulator of a cancer cell's ability to survive under oxygen deprivation. Active compounds 
included three CPT analogues [TPT (3), CPT 20-ester (S) (186), and 9-glycineamido-20(S)-
CPT HCl (187)]. 139
The best characterized compound (3) inhibited both hypoxia (1% O2)- and iron chelator 
(desferoxime; DFO)-induced HIF-1 activation at submicromolar concentrations. Compound 
3 inhibited HIF-1 by decreasing HIF-1α protein translation in a topo I-dependent, oxygen-
independent manner.140 The HIF-1 inhibitory activity of 3 was reversible and schedule-
dependent in vitro (U251 cells), and required a daily (not intermittent) administration 
schedule in vivo (U251 tumor xenograft model).139 Hence, these drugs may have other 
desirable activities against solid tumors that are independent of topo I poisoning. The 
therapeutic potential of TPT (3) as a HIF-1 inhibitor has been reviewed recently.142 This 
critical clue also prompted Jones and co-workers143 to synthesize several 5-substituted CPT 
analogs through an efficient microwave-mediated procedure. Among the newly synthesized 
compounds, a 5-fluoroethyl CPT analog showed potent HIF-1a inhibitory activity with an 
inhibitory rate of 88% at 10 μM.
More recently, Klausmeyer et al.144 isolated and identified four bioactive CPTs from an 
extract of Ophiorrhiza trichocarpon, which reduced hypoxia induction to 22% of control in 
U251-HRE cells and exhibited an EC50 of 0.21 μg/mL with minimal effect on U251-pGL3 
cells.
2.8. Other biological activities
A study by Clements et al.145 showed CPT was not only capable of inhibiting endothelial 
cell growth in a non-toxic manner, but also it inhibited angiogenic growth. In a study to 
investigate the antiangiogenic and antitumor effects of oral ST1481 (gimatecan) in human 
tumor xenografts, Petrangolini et al.146 suggested that the antiangiogenic properties of 
ST1481 could possibly contribute to its antitumor potential and that this effect might be 
enhanced by continuous low-dose treatment. Recent results have shown that CPT-11 is an 
effective inhibitor of angiogenesis and provide strong implications for wider clinical 
application of this drug for colon cancer.147 This observation demonstrates that, besides the 
tumoricidal activity, CPT may have indirect antitumor activity due its anti-angiogenic 
activity and, thus, may have clinical relevance in treating other conditions such as restenosis 
and psoriasis.
In addition, CPT (10–8 M to 10–6 M) significantly inhibited secretion of newly synthesized 
collagenous proteins into conditioned media by 50%. CPT (10–8 M to 10–6 M) caused a 
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significant dose-dependent inhibition of COL1A2 mRNA levels and COL1A2 promoter 
activity by as much as 60%. The inhibitory effect of CPT on collagen production by 
fibroblasts from patients with systemic sclerosis suggests that CPT may be effective in 
limiting fibrosis in such patients.148 Furthermore, CPT has also proved effective in the 
treatment of rheumatoid arthritis because it reduces the activation of the complement 
system.149, 150
Other biological activities of CPT are also receiving increased interest, it has been reported 
that CPT-11 (4) inhibited acetylcholinesterase activity.151 Inhibition of acetylcholinesterase 
could obviously constitute a dose-limiting factor for utilization of the drug. While the 
reports described above represent a solid foundation, a thorough understanding of the 
manner by which CPT may affect cellular function at loci other than topo I is still in its 
infancy.
More recently, the neurotoxic activity of CPT in cultured cerebellar granule neurons has 
been investigated. The screening results showed that CPT-induced neurotoxicity may be due 
to induction of protein–DNA cross-links and other unknown drug-related interactions rather 
than inhibition of topo I activity alone. 152
The variety of biological activities and medicinal applications exhibited by CPT analogues 
are impressive. Additional systemic investigations of the biological activities utilizing 
numerous compounds should further uncover new physiological information and medicinal 
uses for CPT analogues.
3. Conclusion
Almost five decades after CPT's first isolation, CPT-based drugs remain appealing to many 
researchers worldwide and more CPT analogues are emerging as promising 
chemotherapeutic agents. The discovery of Topo I as CPT's therapeutic target opened a new 
area for anticancer drug development. The tremendous efforts in this field included the total 
syntheses or semisyntheses of CPTs, which have been crucial to make new anticancer drugs 
of this family possible. This review has summarized up-to-date coverage of CPTs in regard 
to structure modification and anticancer activities from 2004 to 2012. However, the 
expectation and value of CPT as a lead compound go beyond the development of anticancer 
agents, as additional new biological activities have been discovered. Based on such various 
biological activities, CPT will continue to attract tremendous attention and long lasting 
interest from both the academic community and the pharmaceutical industry. On the other 
hand, continued studies on the CPT–DNA–topo I interaction may suggest new directions in 
the development of CPT-related biological molecules. Interest in CPTs will undoubtedly 
remain high based both on the current pharmaceutical potential and the further discovery of 
new and better drugs based on varied biological activities.
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Structures of camptothecin (1) and camptothecin sodium salt (2).
Liu et al. Page 23













Liu et al. Page 24














Structures of CPT analogs in clinical practice or clinical trials.
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CPT prodrugs and delivery systems currently in clinical trials.
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Structures of 7-substituted lipophilic CPTs (20-23).
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Structures of 7-acyl-CPT derivatives (67,68).
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Structures of 10-position substituted heterocyclic derivatives (74-77).
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Structures of 10-arylcamptothecins (79,80).
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Structures of derivatives containing 1,3-oxazine ring (87, 88).
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Structure of compound 89.
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Structures of glucuronide derivatives 90 and 91.
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Structure of 14-aza-CPT (92).
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Structure of thio-CPT 93.
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Structures of 14-amino-CPTs 94 and 95.
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Structures of C5-substituted analogues (96-98).
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Structure of compound 99.
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Structures of compounds 113 and 114.
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Structures of spin-labeled CPTs (115-119).
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Structures of compounds 120 and 121.
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Structures of 9-benzylideneamino hCPT derivatives (122-125).
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Structures of 7-trifluoromethylated homocamptothecin derivatives (150-152).
Liu et al. Page 43














Structures of 7-acyl homocamptothecin derivatives (161-163).
Liu et al. Page 44














Structure of compound 164.
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Structure of compound 165.
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Structure of compound 166.
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Structures of compounds 167 and 168.
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Structures of compounds 169 and 170.
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Structures of compounds 171-179.
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Structures of compounds 180–183.
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Structures of compounds 184 and 185.
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Structures of compounds 186 and 187.
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Table 1
Cytotoxic Activity (IC50, μM) of 7-(Aryliminomethyl)-CPT Derivatives 24–40.
Compd R1 R2 R3 H460/IC50 (μM)
24 CH3 H H 0.11
25 Cl H H 0.075
26 OCH3 H H 0.058
27 SCH3 H H 0.066
28 C(CH3)3 H H 0.065
29 OH H H 0.032
30 CH3 CH3 H 0.156
31 S-S-o-NH2-Ph H H 0.049
32 H H CH3 0.18
33 H H Cl 0.086
34 H H OCH3 0.166
35 H H SCH3 0.074
36 H H C(CH3)3 0.09
37 H H OH 0.22
38 H H S-p-NH2-Ph 0.24
39 H H S-S-p-NH2-Ph 0.387
40 H H NO2 0.28
TPT (3) ---- ---- 1.38
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Table 2
Cytotoxic Activity (IC50, μM) of Compounds 41–52.
Compd R1 R2 H460/IC50 (μM)
41 CH2OH H 0.21
42 CHO H 0.058
43 CHO OH 6.96
44 CHO OCH3 6.00
45 CN H 0.428
46 CN OH 9.86
47 CN OCH3 0.67
48 CH=NOC(CH3)3 H 0.23
49 CH=NOC(CH3)3 OH 0.36
50 CH=NOC(CH3)3 OCH3 0.32
51 CH=NOCH2CH2NH2 H 2.53
52 CH=NOH H 0.23
TPT (3) CH2-N(CH3)2 OH 1.18
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Table 3
Cytotoxic Activity (IC50, μM) of 7-Cycloalkyl-CPT Derivatives 53–66.
Compd R1 R2 IC50 (μM)
A549/ATCC HT-29
53 cyclopropyl H 0.12 0.12
54 cyclobutyl H 0.05 0.61
55 cyclopentyl H 0.066 0.094
56 cyclohexyl H 0.024 0.02
57 cycloheptyl H 0.015 0.14
58 cyclooctyl H 0.36 0.45
59 H OH 0.11 0.21
60 cyclopentyl OH 0.071 0.058
61 cycloheptyl OH 0.003 0.012
62 H OMe 0.04 0.076
63 cyclobutyl OMe 0.011 0.041
64 cyclopentyl OMe 0.031 0.031
65 cyclohexyl OMe 0.039 0.035
66 cycloheptyl OMe 0.056 0.025
CPT H H 0.047 0.12
TPT (3) ---- ---- 0.36 0.41
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Table 4
Cytotoxic Activity (IC50, μM) of 7-Alkynyl CPT Derivatives 69–74.
Compd IC50 (μM)
Esophageal (Eca-109) Leukemia (K562) Bladder (5637) Gastric (SGC7901)
69 54.8 0.383 1.792 45.4
70 63.9 0.013 0.001 39.2
71 6.8 0.159 0.469 12.0
72 31.3 0.652 2.708 44.7
73 65.2 0.202 0.78 35.2
74 108.6 0.088 0.233 2558.7
SN-38 67.1 0.001 0.001 23.6
TPT (3) 389.5 0.383 1.189 152.0
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Table 5
Cytotoxic Activity (IC50, μM) of 7-Ethyl-9-alkyl-CPT Derivatives 81–86.
Compd R1 R2 R3 IC50 (μM)
Bel-7402 HCT-116
81 OH CH2CH=CH2 CH2CH3 2.75 0.014
82 CH2OH CH2CH=CH2 CH2CH3 2.16 0.068
83 OH CH2CH2CH3 CH2CH3 3.01 0.012
84 CH2OH CH2CH2CH3 CH2CH3 3.84 0.153
85 CH2OH CH2CH3 CH2CH3 2.40 0.061
86 OH CH2CH3 CH2CH3 2.01 0.023
SN-8 OH H CH2CH3 3.19 0.007
HCPT OH H H 2.47 0.148
TPT (3) ---- ---- ---- 3.98 0.100
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Table 6
Cytotoxic activity (IC50, μM) of nitrogen-based CPT ester derivatives 100–112.
Compd R IC50 (μM)
KB KB/VCR A2780 A549 HCT-8 Bel7402
100 0.043 0.100 0.056 0.051 0.042 0.009
101 0.013 0.080 0.027 0.010 0.023 0.008
102 0.054 0.384 0.067 0.068 0.089 0.059
103 0.067 0.092 0.069 0.091 0.076 0.064
104 0.007 0.179 0.016 0.046 0.052 0.018
105 0.043 0.084 0.056 0.055 0.008 0.007
106 0.065 0.129 0.089 0.088 0.066 0.065
107 0.056 0.098 0.092 0.094 0.055 0.051
108 0.071 0.297 0.291 0.255 0.077 0.077
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Compd R IC50 (μM)
KB KB/VCR A2780 A549 HCT-8 Bel7402
109 0.055 0.177 0.080 0.280 0.065 0.047
110 0.009 0.086 0.083 0.088 0.009 0.009
111 0.673 >1.0 >1.0 >1.0 0.862 0.783
112 0.716 >1.0 >1.0 >1.0 0.817 0.802
CPT ---- 0.009 0.009 0.007 0.008 0.007 0.007
TPT (3) ---- 0.062 0.339 0.058 0.087 0.074 0.078
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Table 7
Cytotoxic activity (IC50, μM) of 7-alkenyl-hCPTs 126–141.
Compd R1 R2 IC50 (μM)
A-549
126 H 4-NO2-C6H4 0.259
127 H Ph 0.493
128 H 2-Br-C6H4 3.25
129 H 4-NC-C6H4 2.62
130 H 3-F-C6H4 0.431
131 H 2-F-C6H4 4.38
132 H C6F5 4.68
133 H 4-Me-C6H4 3.35
134 H 2-O-C6H4 2.65
135 H 3-O-C6H4 3.15
136 H 2-CF3-C6H4 0.387
137 H 4-CF3-C6H4 20.6
138 H t-BuOOC 0.811
139 H EtOOC 2.54
140 H MeOOC 0.486
141 Me EtOOC 5.29
TPT (3) ---- ---- 2.64
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Table 8
Cytotoxic Activity (IC50, μM) of Phosphodiester- and Phosphotriester-hCPTs 142–149.
Compd R1 R2 IC50 (μM)
A549 MDA-MB-435 LOVO
142 H Et 11.40 5.26 7.24
143 H C6H5CH2 29.35 10.77 9.31
144 Et Et 8.05 0.79 1.26
145 iso-Pr iso-Pr 11.39 3.40 5.56
146 Bu Bu 2.84 0.51 0.91
147 pentyl pentyl 2.30 0.72 1.19
148 cetyl cetyl >100 >100 >100
149 CF3CH2 CF3CH2 15.51 0.22 5.42
TPT (3) ---- ---- 0.04 <0.001 0.02
CPT-11 (4) ---- ---- 4.61 1.14 4.99
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Table 9
Cytotoxic Activity (IC50, μM) of Compounds 153–160.
Compd R1 R2 IC50 (μM)
HCT-116 A549
153 H H 14.2 49.2
154 OCH3 H 4.4 4.7
155 OCH2O OCH2O 2.1 1.2
156 OCH2CH2O OCH2CH2O 4.9 4.6
157 H H 49.3 16.8
158 OCH3 H 10.6 4.8
159 OCH2O OCH2O 3.1 3.1
160 OCH2CH2O OCH2CH2O 3.4 2.9
10-HCPT ---- ---- 31.2 33.6
CPT ---- ---- 22.9 33.8
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Table 10
Antifeedant activity of CPT analogues against third-instar larvae of Spodoptera litura (Test Concentration = 
1000 μL).
Compd Antifeedant activity (%)


























Liu et al. Page 65
Table 11
Antitrypanosomal activity of CPT derivatives that retain the parent ring system.
Compd EC50 (μM)
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